NASDAQ$RPTX
Repare Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Repare Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2023.
Repare Therapeutics reported a decrease in revenue from collaboration agreements for the three-month period ended December 31, 2023, due to lower deferred revenue recognized from the Roche and BMS collaborations. The company's cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023.
- Advanced each of the four programs in its portfolio and set the stage for meaningful data readouts and new clinical trial starts this year.
- Presented initial positive data from its ongoing Phase 1 MYTHIC trial evaluating lunresertib alone and in combination with camonsertib.
- Announced a partnership with Debiopharm to explore the potential clinical synergy of Debio 0123 and lunresertib.
- Dosed the first patient in the multicenter, open-label Phase 1 dose escalation trial of RP-1664 in adult and adolescent patients with TRIM37-high solid tumors in February 2024.
Headline financials
Revenue & EPS history
Repare Therapeutics · Revenue · Quarterly
$13M
Forward guidance
Repare Therapeutics anticipates several milestones in 2024, including initiating a Phase 1/1b clinical trial of lunresertib and Debio 0123, reporting initial data from multiple trials, disclosing additional camonsertib clinical development plans, and initiating a Phase 1 dose finding trial of RP-3467.
Tailwinds
- Initiate a Phase 1/1b clinical trial of lunresertib and Debio 0123 in the first half of 2024.
- Report initial data from the Phase 1 MINOTAUR trial in the first half of 2024.
- Disclose additional camonsertib clinical development plans in the second quarter of 2024.
- Report data from the dose expansion cohorts of the Phase 1 MYTHIC trial in the second half of 2024.
- Initiation of a Phase 1 dose finding trial of RP-3467 in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-0.1%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.7%
Q2 2023
Best reaction
-13.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -2.4% | +27.5% | +26.3% | |
| Q2 2025 | +0.0% | +3.3% | +11.2% | |
| Q1 2025 | +3.8% | +0.0% | +9.1% | |
| Q4 2024 | -1.7% | +0.9% | -9.4% | |
| Q3 2024 | -0.6% | -4.4% | -13.5% | |
| Q2 2024 | -4.8% | -8.3% | -11.9% | |
| Q1 2024 | +11.5% | +7.7% | +17.4% | |
| Q4 2023 | +4.4% | -0.6% | -29.9% | |
| Q3 2023 | -6.6% | — | — | |
| Q2 2023 | +19.7% | — | — | |
| Q1 2023 | +1.5% | — | — | |
| Q4 2022 | +2.0% | — | — | |
| Q3 2022 | +7.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.2% | — | — | |
| Q4 2021 | +0.4% | — | — | |
| Q3 2021 | +2.2% | — | — | |
| Q2 2021 | -0.2% | — | — | |
| Q1 2021 | +0.5% | — | — | |
| Q4 2020 | -13.5% | — | — | |
| Q3 2020 | -2.3% | — | — | |
| Q2 2020 | +2.6% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro